1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Analysis of healthcare provider practice patterns from individual patient cases entered into an online treatment decision tool for chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Rosenthal, K. M.; Awan, F. T.; Coutre, S.; Jones, J. A.; Sharman, J. P.; Obholz, K. L.; Zelenetz, A. D.
    Blood (2017)

    Fulltext@MSK | Save
  • Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) versus BR alone: Results from a randomized phase 2 study
    Meeting Abstract

    Sehn, L. H.; Herrera, A. F.; Matasar, M. J.; Kamdar, M.; McMillan, A. K.; Kim, T. M.; Kim, W. S.; Hertzberg, M.; Ozcan, M.; Penuel, E.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Venetoclax plus rituximab is superior to bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia - Results from pre-planned interim analysis of the randomized phase 3 Murano study
    Meeting Abstract

    Seymour, J. F.; Kipps, T. J.; Eichhorst, B. F.; Hillmen, P.; D'Rozario, J. M.; Assouline, S.; Owen, C. J.; Gerecitano, J.; Robak, T.; De la Serna, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Expression of major histocompatibility complex (MHC) class II, but not MHC class I, predicts outcome in patients with classical Hodgkin lymphoma (cHL) treated with nivolumab (programmed death-1 [PD-1] blockade)
    Meeting Abstract

    Roemer, M. G. M.; Redd, R. A.; Cader, F. Z.; Pak, C. J.; Abdelrahman, S.; Ouyang, J.; Sasse, S.; Younes, A.; Fanale, M. A.; Santoro, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Adults receiving defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after hematopoietic stem cell transplantation (HSCT): Final results from the expanded-access program
    Meeting Abstract

    Richardson, P. G.; Antin, J. H.; Giralt, S. A.; Ryan, R. J.; Liang, W.; Hume, R. L.; Tappe, W. M.; Kernan, N. A.
    Blood (2017)

    Fulltext@MSK | Save
  • Results from ENESTgoal: A phase 2 study of treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) who switched from imatinib to nilotinib
    Meeting Abstract

    Ritchie, E. K.; Catchatourian, R.; Klisovic, R. B.; Pinilla-Ibarz, J.; Deininger, M. W.; Erba, H. P.; Radich, J. P.; Savona, M. R.; Dautaj, I.; Purkayastha, D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Enhancing CAR T cell anti-tumor efficacy through secreted single chain variable fragment (scFv) immune checkpoint blockade
    Meeting Abstract

    Rafiq, S.; Jackson, H. J.; Yeku, O.; Purdon, T. J.; van Leeuwen, D. G.; Curran, K. J.; Ahmed, R. N.; Cullen, G. D.; Yan, S.; Wang, P.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Genomic landscapes in elderly AML
    Meeting Abstract

    Rapaport, F.; Baslan, T.; Wang, L.; Sheridan, C.; Lee, T.; Hricik, T.; de Massy, M. R.; Telis, L.; Neelamraju, Y.; Medina, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Population-scale identification of clonal hematopoiesis derived mutations in solid tumor mutation profiling
    Meeting Abstract

    Ptashkin, R.; Coombs, C. C.; Hyman, D. M.; Solit, D.; Baselga, J.; Arcila, M. E.; Ladanyi, M.; Levine, R. L.; Berger, M. F.; Zehir, A.
    Blood (2017)

    Fulltext@MSK | Save
  • Clonal heterogeneity in differentiation response and resistance to the IDH2 inhibitor enasidenib in acute myeloid leukemia
    Meeting Abstract

    Quek, L.; David, M.; Kennedy, A.; Metzner, M.; Amatangelo, M.; Shih, A. H.; Stoilova, B.; Karamitros, D.; Quivoron, C.; Heiblig, M.; more...
    Blood (2017)

    Fulltext@MSK | Save